Results 101 to 110 of about 5,401 (177)

Efectividad de un inhibdor de la vía de hedgehog (vismodegib) en pacientes con cáncer basocelular

, 2016
Introducción: El Cáncer Basocelular (CBC) es el subtipo de cáncer no melanoma más frecuente en el mundo, con comportamiento maligno derivado de células no queratinizadas de la capa basal de la epidermis, se presenta principalmente en personas de raza ...
Navarro Pichot, Uriel Edu
core  

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma

Cancer Management and Research, 2013
Muzafar A Macha,1 Surinder K Batra,1,2 Apar Kishor Ganti3,41Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical ...
Macha MA, Batra SK, Ganti AK
doaj  

A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastoma. [PDF]

Acta Oncol
Abdi S, Poikonen-Saksela P, Halonen P, Tynninen O, Reardon DA, Hernberg M.   +5 more
europepmc   +1 more source

Ldha Regulates Osteosarcoma Lung Metastasis through Hedgehog Signaling. [PDF]

Cancer Res Commun
Maki R, Komura S, Nagano A, Niwa A, Tomita H, Imai Y, Akiyama H.   +6 more
europepmc   +1 more source

Transcriptomic Analysis of Early-Stage Basal Cell Carcinomas in Murine Skin Following Topical Treatments With Ablative Fractional Laser and Vismodegib

Recent studies have demonstrated that ablative fractional laser (AFL) can inhibit the hedgehog pathway, enhance immune infiltration and clear basal cell carcinomas (BCCs) in murine models.
Hædersdal, Merete, Litman, Thomas, Pedersen, Kristian Kåber, Olesen, Uffe Høgh   +3 more
core   +1 more source

Advanced Basal Cell Carcinoma in a Geriatric Patient: A Case Report and Ethical Considerations. [PDF]

Cureus
Velázquez Arenas L, Garay Enriquez S, Gómez Guerra D.   +2 more
europepmc   +1 more source

Synthesis and preliminary assessment of fluorescent probes based on the competitive GPCR antagonists vismodegib and masupirdine. [PDF]

RSC Adv
Alexander C, Cheung TL, Kumar CA, Hor CHH, Li H, Zou X, Parker D.   +6 more
europepmc   +1 more source

GLIS3 drives epithelial-mesenchymal transition and cancer stem-like traits in stomach adenocarcinoma via TGFBR3-Hedgehog signaling. [PDF]

Front Oncol
Xiao Q, Deng H, Li J, Zheng Y, Zhang Y.
europepmc   +1 more source

Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma

JAAD Case Reports, 2021
Jaeyoung Yoon, MD, PhD
doaj   +1 more source

Clinical Outcomes of Sonidegib in Vismodegib-Exposed Locally Advanced Basal Cell Carcinoma: Insights From a Multicenter Descriptive Study. [PDF]

J Skin Cancer
Prados-Carmona A, Martínez-Pérez M, Velasco-Amador JP, Almazán-Fernández FM, Ruiz-Villaverde R.   +4 more
europepmc   +1 more source